Hosted on MSN13m
Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower Growth Outlook To Chase Obesity Drug BoomNYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback